Supplementary Materials

Supplementary Material for:

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms

Ofir Wolach, Rob S. Sellar, Kimberly Martinod, Deya Cherpokova, Marie McConkey, Ryan J. Chappell, Alexander J. Silver, Dylan Adams, Cecilia A. Castellano, Rebekka K. Schneider, Robert F. Padera, Daniel J. DeAngelo, Martha Wadleigh, David P. Steensma, Ilene Galinsky, Richard M. Stone, Giulio Genovese, Steven A. McCarroll, Bozenna Iliadou, Christina Hultman, Donna Neuberg, Ann Mullally, Denisa D. Wagner, Benjamin L. Ebert*

*Corresponding author. Email: bebert{at}

Published 11 April 2018, Sci. Transl. Med. 10, eaan8292 (2018)
DOI: 10.1126/scitranslmed.aan8292

This PDF file includes:

  • Fig. S1. Complementary studies of NET formation in neutrophils derived from MPN patients.
  • Fig. S2. Phenotype reminiscent of PV in mice with Jak2V617F-driven MPN.
  • Fig. S3. Neutrophil, platelet, RBC, and fibrin thrombus content.
  • Fig. S4. The effect of DNase treatment on thrombosis rate in an IVC partial ligation thrombosis model.
  • Fig. S5. IVC full ligation thrombosis model in Pad4+/+ and Pad4−/− mice.
  • Fig. S6. IVC full ligation thrombosis model in Jak2WT and Jak2V617F with and without ruxolitinib treatment.
  • Fig. S7. Neutrophil activation and ROS production in neutrophils from Jak2WT and Jak2V617F mice.
  • Fig. S8. Platelet function in Jak2WT and Jak2V617F mice.
  • Fig. S9. NET formation in neutrophils derived from mice engrafted with Jak2V617F-expressing Pad4+/+ or Pad4−/− cells.
  • Fig. S10. Blood cell counts from the Pad4/Jak2V617F retroviral bone marrow transplant model.
  • Fig. S11. Differences in age between persons with and without CHIP.
  • Table S1. Patient characteristics (not treated with JAK inhibitors).
  • Table S2. Patient characteristics (JAK inhibitor–treated).
  • Table S3. Comparing NET formation between groups.
  • Table S4. ICD-10 codes used to identify thrombosis in the case-control cohort.
  • Table S5. Summary of thrombosis rates in the case-control study broken down by cohort (schizophrenia versus healthy controls) and type of clonal hematopoiesis.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S6 (Microsoft Excel format). Primary data file (provided in Excel format).